In Rheumatoid arthritis Rheumatoid arthritis is an autoimmune condition where your body’s immune system attacks the joints. Mext 7.5 F Combipack stops that from happening and can relieve the symptoms of this condition such as pain, swelling, and stiffness in your joints. It can also slow down joint damage, reduce disability, and enable you to be as active for as long as possible. It may 4-12 weeks take weeks before you notice any benefits. You should continue taking it until your doctor says it is okay to stop using the medicine. Folic acid present in Mext 7.5 F Combipack help prevent a folate deficiency.
Caution is advised when consuming alcohol with Mext 7.5 F Combipack. Please consult your doctor.
Mext 7.5 F Combipack is highly unsafe to use during pregnancy. Seek your doctor's advice as studies on pregnant women and animals have shown significant harmful effects to the developing baby.
Mext 7.5 F Combipack is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Mext 7.5 F Combipack may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Mext 7.5 F Combipack is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Mext 7.5 F Combipack may not be needed in these patients. Please consult your doctor.
Mext 7.5 F Combipack is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Mext 7.5 F Combipack may not be needed in these patients. Please consult your doctor.
If you miss a dose of Mext 7.5 F Combipack, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Molekule India Pvt Ltd || ₹14.5/tablet (25% cheaper)